These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28629442)

  • 1. Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis.
    Gauthier G; Guérin A; Zhdanava M; Jacobson W; Nomikos G; Merikle E; François C; Perez V
    BMC Psychiatry; 2017 Jun; 17(1):222. PubMed ID: 28629442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States.
    Zhu L; Ferries E; Suthoff E; Namjoshi M; Bera R
    J Manag Care Spec Pharm; 2022 Nov; 28(11-a Suppl):S2-S13. PubMed ID: 36242598
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
    Khandker RK; Kruzikas DT; McLaughlin TP
    J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns, health care resource utilization, and costs associated with use of atypical antipsychotics as first vs subsequent adjunctive treatment in major depressive disorder.
    Jain R; Laliberté F; Germain G; Mahendran M; Higa S; Harrington A; Parikh M
    J Manag Care Spec Pharm; 2023 Aug; 29(8):896-906. PubMed ID: 37523314
    [No Abstract]   [Full Text] [Related]  

  • 5. Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder.
    Ta JT; Sullivan SD; Tung A; Oliveri D; Gillard P; Devine B
    J Manag Care Spec Pharm; 2021 Feb; 27(2):223-239. PubMed ID: 33506730
    [No Abstract]   [Full Text] [Related]  

  • 6. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.
    Li G; Zhang L; DiBernardo A; Wang G; Sheehan JJ; Lee K; Reutfors J; Zhang Q
    PLoS One; 2020; 15(9):e0238843. PubMed ID: 32915863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden associated with inadequate antidepressant medication management among patients with depression and known cardiovascular diseases: insights from a United States-based retrospective claims database analysis.
    Bangalore S; Shah R; Gao X; Pappadopulos E; Deshpande CG; Shelbaya A; Prieto R; Stephens J; Chambers R; Schepman P; McIntyre RS
    J Med Econ; 2020 Mar; 23(3):262-270. PubMed ID: 31665949
    [No Abstract]   [Full Text] [Related]  

  • 8. Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.
    Zhdanava M; Teeple A; Pilon D; Shah A; Caron-Lapointe G; Joshi K
    J Med Econ; 2023; 26(1):691-700. PubMed ID: 37130075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis.
    Pilon D; Joshi K; Sheehan JJ; Zichlin ML; Zuckerman P; Lefebvre P; Greenberg PE
    PLoS One; 2019; 14(10):e0223255. PubMed ID: 31600244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom.
    Denee T; Ming T; Waller J; Bailey T; Rajkovic-Hooley O; Middleton-Dalby C; Le HH; Zhang Q; McCrone P; Taylor D
    Curr Med Res Opin; 2021 Feb; 37(2):311-319. PubMed ID: 33253055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world treatment modalities, health care resource utilization, and costs among commercially insured patients with newly diagnosed major depressive disorder in the United States.
    Pizzicato LN; Xie RZ; Yang Y; Grabner M; Chapman RH
    J Manag Care Spec Pharm; 2023 Jun; 29(6):614-625. PubMed ID: 37276037
    [No Abstract]   [Full Text] [Related]  

  • 12. Association Between Cognitive Function and Health Care Costs 3 Months and 6 Months After Initiating Antidepressant Medication for Depressive Disorders.
    Walker V; Patel H; Kurlander JL; Essoi B; Yang J; Mahableshwarkar AR; Samp JC; Akhras KS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):742-52, 752a-752e. PubMed ID: 26308222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Annual costs among patients with major depressive disorder and the impact of key clinical events.
    Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
    [No Abstract]   [Full Text] [Related]  

  • 14. Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder.
    Schultz J; Joish V
    Psychiatr Serv; 2009 Dec; 60(12):1604-11. PubMed ID: 19952150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
    Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
    CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Earlier Versus Later Augmentation with an Antipsychotic Medication in Patients with Major Depressive Disorder Demonstrating Inadequate Efficacy in Response to Antidepressants: A Retrospective Analysis of US Claims Data.
    Yermilov I; Greene M; Chang E; Hartry A; Yan T; Broder MS
    Adv Ther; 2018 Dec; 35(12):2138-2151. PubMed ID: 30456519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
    Seetasith A; Greene M; Hartry A; Burudpakdee C
    J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Service Use and Health Care Costs of Medicaid Beneficiaries with Treatment-Resistant Depression.
    Olfson M; Amos TB; Benson C; McRae J; Marcus SC
    J Manag Care Spec Pharm; 2018 Mar; 24(3):226-236. PubMed ID: 29485948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
    Robinson RL; Long SR; Chang S; Able S; Baser O; Obenchain RL; Swindle RW
    J Manag Care Pharm; 2006; 12(1):43-54. PubMed ID: 16420107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine.
    Cui Z; Faries DE; Zhao Y; Novick D; Liu X
    J Med Econ; 2011; 14(5):662-72. PubMed ID: 21892857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.